bioRxiv Cancer Biology· Griesler, B., Hagemann, S., Winkler, R., Wedler-Geyer, A., Misiak, C., Misiak, D., Rausch, A., Luetzkendorf, J., Mueller, T., Mir, K. U. I., Ihling, C., Otto, F. W., Sinz, A., Klusmann, J.-H., Heuser, M., Mueller, L. P., Bley, N., Huettelmaier, S. ·· 23 hours agoPickScore67
Targeting IGF2BP1 Creates a Mitotic Vulnerability in Colorectal Carcinoma
In brief
A bioRxiv preprint shows that targeting IGF2BP1 disrupts mitosis in colorectal cancer, and BTYNB combined with paclitaxel produces synergistic effects in cell models. IGF2BP1 is highly expressed in CRC, rises with tumor stage, and correlates with poorer survival; its genetic depletion or pharmacological inhibition reduces cell viability and induces mitotic abnormalities and apoptosis.
Why it matters
BTYNB plus paclitaxel showed synergy in four IGF2BP1-positive patient-derived organoids, providing experimental support for combination therapy in colorectal cancer.
Source: bioRxiv Cancer Biology · biorxiv.org